english.prescrire.org > Spotlight > 100 most recent

Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

Isotretinoin: too many pregnancies still at risk

Despite a series of measures, unborn children are still being exposed to isotretinoin during pregnancy, with a risk of serious malformations and/or neuropsychiatric disorders.
1 April 2022

Down with the "p value"! A move to democratise health information

1 April 2022

• Down with the decline in vigilance! Mind your p's and q's

In today's ever more skewed world, it's more important than ever to use every tool at one's disposal to determine if a result is significant. Or just plain old fishy.
1 April 2022

Watch the video of the webinar "Prescrire, A Critical Eye on New Drugs"

 VIDEO  How many new drugs offer an advantage and how many bring nothing new? Prescrire has been answering this key question since 1981. In a March 2022 webinar organised by Consilium Scientific, Pierre Chirac of Prescrire explained the reason for Prescrire's existence, the people behind it, its operations, its main achievements, and its limitations.
21 March 2022

Ivacaftor + tezacaftor + elexacaftor (Kaftrio°) in cystic fibrosis with at least one F508del mutation: respiratory symptoms alleviated in the short term

FEATURED REVIEW Is this triple therapy more effective than dual therapy at reducing the incidence of pulmonary exacerbations and alleviating symptoms? Does it slow disease progression and extend survival? What adverse effects are associated with the addition of elexacaftor?
Full review (4 pages) available for download by subscribers.
1 March 2022

In the March issue of Prescrire International: Revision of European pharmaceuticals legislation

FREE DOWNLOAD Prescrire has responded to a public consultation on a planned revision of Directive 2001/83 "on the Community code relating to medicinal products" and Regulation 726/2004 "laying down Community procedures for the authorisation and supervision of medicinal products (...) and establishing a European Medicines Agency".
Full text available for free download.
1 March 2022

Rational deprescribing

 Editorial  The term "deprescribing" has been used more and more in recent years. But deprescribing, like prescribing, is not without risk.
1 March 2022

The Prescrire Awards for 2021: two "Pilule d'Or" Awards, and 5 drugs on the "Honours List". Details in the March issue of Prescrire International

ThePrescrire Awards independent French medical journal Prescrire conferred two "Pilule d'Or" ("Golden Pill") Awards for 2021; 5 drugs made the "Honours List", and 2 drugs were deemed "Noteworthy". Details for the Drug and Information Awards, published in the March issue of Prescrire International, are available HERE.
1 March 2022

Tramadol: achieving successful withdrawal after prolonged use

Tramadol, an opioid analgesic authorised for relief of moderate to severe pain, carries a risk of dependence. Discontinuation is sometimes difficult and can require strong patient motivation as well as long-term medical support.
1 March 2022

Benzodiazepines: risk of persistent use even after brief treatment

Occasional benzodiazepine use is often followed by repeated use, and there is a risk of addiction. When a benzodiazepine is justified, it is important to plan its withdrawal, together with the patient, as soon as treatment starts.
1 March 2022

1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90